Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.66 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.66 |
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 13/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 13/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 11/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 11/20 | 0.51 |
| ▸ | MGMT | P16455 | 4/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butylamine SCHEMBL27790885 | 0.84 | CDK2 (0.71) | CDK2PDPK1GDADPP4MAP3K5 | |
| Tetrabuthylammonium SCHEMBL200612 | 0.82 | CDK2 (0.68) | CDK2PDPK1GDADPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL24053 | 0.79 | PDPK1 (1.00) | CDK2PDPK1GDADPP4MAP3K5 | |
| SCHEMBL532461 | 0.79 | CDK2 (0.66) | CDK2PDPK1GDADPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL27891733 | 0.78 | PDPK1 (0.96) | CDK2PDPK1GDADPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL28206545 | 0.78 | PDPK1 (0.96) | CDK2PDPK1GDADPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL8757979 | 0.78 | PDPK1 (0.96) | CDK2PDPK1GDADPP4MAP3K5 | |
| SCHEMBL5935896 | 0.76 | CDK2 (0.61) | CDK2PDPK1GDADPP4 | |
| SCHEMBL1336875 | 0.76 | PDPK1 (0.66) | CDK2PDPK1GDADPP4MAP3K5 | |
| Thioguanine SCHEMBL183648 | 0.76 | PDPK1 (0.66) | CDK2PDPK1GDADPP4MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4560315-A2 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | claimed |
| EP-3980554-B1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | HOFFMANN LA ROCHE (CH) | 2025-03-26 | — | — | EP | claimed |
| CN-118931997-A | Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis | 上海飞腾医药科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-20220195497-A1 | HYBRIDIZING all-LNA OLIGONUCLEOTIDES | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2022-06-23 | — | — | US | claimed |
| EP-3980554-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2022-04-13 | — | — | EP | claimed |
| CN-113939599-A | Hybrid all-LNA oligonucleotides | 豪夫迈·罗氏有限公司 | 2022-01-14 | — | — | CN | claimed |
| WO-2020245377-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-10 | — | — | WO | claimed |
| CN-105440281-A | Polyamide resin, and preparation method therefor and molded product thereof | TORAY ADVANCED MAT RES LABORATORIES (CHINA) CO LTD | 2016-03-30 | — | — | CN | claimed |
| WO-2013090873-A1 | A COMPOSITION AND METHOD FOR REDUCING CYANURIC ACID IN RECREATIONAL WATER | HAVILAND PRODUCTS COMPANY (US) | 2013-06-20 | — | — | WO | claimed |
| US-20100286084-A1 | Oligomer-Nucleoside Phosphate Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | claimed |
| EP-0861841-B1 | PROCESS FOR PRODUCING 2-AMINO-6-IODOPURINE | SUMIKA FINE CHEMICALS COMPANY (JP) | 2001-04-04 | — | — | EP | claimed |
| US-5994541-A | Process for producing 2-amino-6-iodopurine | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 1999-11-30 | — | — | US | claimed |
| US-5817799-A | 2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-10-06 | — | — | US | claimed |
| EP-0861841-A1 | PROCESS FOR PRODUCING 2-AMINO-6-IODOPURINE | SUMIKA FINE CHEMICALS Company, Limited (JP) | 1998-09-02 | — | — | EP | claimed |
| EP-0540686-B1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1995-08-30 | — | — | EP | claimed |
| EP-0540686-A4 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1993-05-26 | — | — | EP | claimed |
| EP-0540686-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES. | US COMMERCE (US) | 1993-05-12 | — | — | EP | claimed |
| WO-1992001700-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1992-02-06 | — | — | WO | claimed |
| JP-11060575-A | — | — | None | — | — | JP | disclosed |
| EP-0294114-A2 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286084-A1 | Oligomer-Nucleoside Phosphate Conjugates | ENTPD5, SLC29A2, SLC29A1 | CDK2 1128/4885PDPK1 2582/4885GDA 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.